Cipla began its remarkable corporate journey in 1935 when it was founded as the Chemical, Industrial and Pharmaceutical Laboratories in Mumbai, India, driven by a nationalistic vision to make the country self-reliant in essential healthcare and medicine production. Over subsequent decades, the enterprise evolved from a modest domestic chemical producer into a global pharmaceutical powerhouse renowned for pioneering affordable access to life-saving medications, particularly its historic breakthrough in supplying low-cost antiretroviral drugs to combat HIV/AIDS across developing nations. Today, the company stands as an international multinational titan, delivering high-quality generic treatments, advanced respiratory devices, and specialized therapies to patients in numerous countries worldwide.
Cipla is not a specific type of generic medicine itself, but it is one of the world's largest and most highly respected manufacturers of generic pharmaceutical products.
The wealthiest leader in the Indian pharmaceutical sector is Dilip Shanghvi, the visionary founder and managing director of Sun Pharmaceutical Industries, whose substantial net worth places him among the richest individuals in the country.
Like all pharmaceutical treatments, the side effect profile of medications manufactured by Cipla varies entirely depending on the specific active chemical ingredient, therapeutic classification, and individual patient physiology.
The founding and promoter family of Cipla includes prominent business leaders, and the third-generation leader representing the family lineage is Samina Vaziralli (born Samina Hamied), who serves as the Executive Vice-Chairperson of the company.
Cipla is widely regarded as a highly reputable, trustworthy, and quality-conscious pharmaceutical manufacturer operating on a global scale.
Cipla is not an American company; it is an Indian multinational pharmaceutical corporation headquartered in Mumbai, India. Although it operates a wholly owned corporate subsidiary known as Cipla USA Inc.
Cipla is a proudly Indian multinational pharmaceutical and biotechnology corporation with its corporate headquarters located in Mumbai, Maharashtra, India.
Cipla expanded its consumer healthcare portfolio by entering into definitive agreements to acquire a one hundred percent equity stake in Inzpera Healthsciences Private Limited.
Umang Vohra currently serves as the Managing Director and Global Chief Executive Officer of Cipla, a prominent position he has held with distinction since assuming the role in 2016.
Cipla operates a substantial commercial footprint within the United States through its dedicated corporate subsidiary, Cipla USA Inc.
Because Cipla manufactures thousands of distinct pharmaceutical formulations ranging from basic analgesics and antibiotics to complex chronic therapies, there is no single set of side effects for a "Cipla tablet.
Cipla is not owned by a single individual family today, as it is a publicly traded multinational corporation whose shares are held by millions of institutional investors, mutual funds, and retail shareholders on major stock exchanges.
Cipla is not a specific painkiller or a single medication; rather, it is a massive, multinational pharmaceutical manufacturing corporation headquartered in India that produces a vast array of different medical treatments across multiple therapeutic c...
Pharmaceutical products manufactured by Cipla are widely recognized as safe and effective, adhering strictly to global quality assurance protocols and regulatory standards mandated by elite health authorities such as the United States Food and Drug A...
Cipla manufactures an extensive and comprehensive catalog of pharmaceutical formulations spanning major therapeutic segments, including both generic and branded prescription drugs.
The highest salaries at Cipla are exclusively awarded to its top-tier executive leadership, specifically the Global Chief Executive Officer, the Chief Financial Officer, and other elite C-suite managing directors who oversee massive international div...
Generic drugs are significantly less expensive than brand-name medications primarily because generic manufacturers do not need to invest the massive financial capital, time, and extensive research required to discover, test, and develop a new chemica...
Cipla has achieved global renown primarily due to its historic role in pioneering affordable access to life-saving medications, most notably when it broke international pricing barriers in the early two thousands by supplying low-cost antiretroviral ...
Cipla maintains a robust and highly strategic corporate presence in the United States, operating primarily through its wholly-owned subsidiary known as Cipla USA Inc.
Cipla USA is a wholly-owned subsidiary of Cipla Limited, the massive multinational pharmaceutical parent corporation headquartered in Mumbai, India.
The primary and most widely recognized brand name under which Cipla manufactures and markets paracetamol is Paracip, available in various dosage strengths including 500 milligrams and 650 milligrams.
Cipla is globally recognized as one of the world's largest and most successful manufacturers of high-quality generic pharmaceuticals.
Umang Vohra serves as the Global Chief Executive Officer and Managing Director of Cipla, leading the multinational pharmaceutical enterprise with a strong focus on operational excellence, global market expansion, and strategic product diversification...
The compensation package for the Global Chief Executive Officer of Cipla, Umang Vohra, is highly structured and typically ranks among the top echelons of executive remuneration within the Indian pharmaceutical industry, reflecting the massive scale a...
Because Cipla is a massive pharmaceutical manufacturing corporation rather than a single chemical substance, it does not treat a specific medical condition.